{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:52:08Z","timestamp":1792057928441,"version":"4.4.0"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with indolent and MCL were eligible. Bortezomib was given at a dose of 1.5 mg\/m<jats:sup>2<\/jats:sup> on days 1, 4, 8, and 11. Patients were required to have received no more than three prior chemotherapy regimens, with at least 1 month since the prior treatment, 3 months from prior rituximab, and 7 days from prior corticosteroids; absolute neutrophil count more than 1,500\/\u03bcL (500\/\u03bcL if documented bone marrow involvement); and platelet count more than 50,000\/\u03bcL. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Twenty-six patients were registered, of whom 24 were assessable. Ten patients had follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had marginal zone lymphoma. The overall response rate was 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL). All responses were durable, lasting from 3 to 24+ months. One patient with MCL achieved a CRu, four achieved a PR, and four had stable disease. One patient with MCL maintained his remission for 19 months. Both patients with marginal zone lymphoma achieved PR lasting 8+ and 11+ months, respectively. Patients with SLL or CLL have yet to respond. Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia). The most common grade 3 toxicities were lymphopenia (n = 14) and thrombocytopenia (n = 7). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.02.050","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T03:00:17Z","timestamp":1103684417000},"page":"676-684","source":"Crossref","is-referenced-by-count":476,"title":["Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Owen A.","family":"O'Connor","sequence":"first","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wright","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Muzzy","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"MacGregor-Cortelli","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stubblefield","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Straus","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Portlock","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Choi","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otila","family":"Dumetrescu","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie","family":"Esseltine","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Trehu","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Adams","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schenkein","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006321828515"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cel lymphoma. Blood 15:619,2000-626,","DOI":"10.1182\/blood.V95.2.619"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1652"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.183"},{"key":"R6","unstructured":"Frankel A, Man S, Elliott P, et al: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719,2000-3728,"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6194"},{"key":"R8","unstructured":"Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071,2001-3076,"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"R10","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505,2002-2511,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90030-6"},{"key":"R13","unstructured":"Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:219,1993-222,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.782"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Harousseau JL, Shaughnessy J Jr, Richardson P: Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 237,2004-256,","DOI":"10.1182\/asheducation-2004.1.237"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"An B, Goldfarb RH, Siman R, et al: Novel dipeptidyl proteasome inhibitors overcome bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed but not normal fibroblasts. Cell Death Differ 12:1062,1998-1075,","DOI":"10.1038\/sj.cdd.4400436"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1861"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Ohshima K, Muta J, Kawasaki C, et al: Bcl10 expression, rearrangement and mutation in MALT lymphoma: Correlation with expression of nuclear factor-kappa-B. Int J Oncol 19:283,2001-289,","DOI":"10.3892\/ijo.19.2.283"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-200111000-00001"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00029-8"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3130"},{"key":"R27","unstructured":"Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M arrest and apoptosis. Mol Cancer Ther 1:841,2002-849,"},{"key":"R28","unstructured":"Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G2-M phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145,2003-1154,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.3"},{"key":"R36","unstructured":"Goy A, Hart S, Pro B, et al: Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphoma. Blood 102,2003,  (abstr 627)"},{"key":"R37","unstructured":"Assouline S, Belch A, Sehn L, et al: A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 102,2003,  (abstr 3358)"},{"key":"R38","unstructured":"O'Connor OA, Srinicasan S, Hernandez F, et al: Oblimersen enhances the antitumor activity of bortezomib in multiple myeloma and non-Hodgkin's lymphoma in preclinical models. Proc Am Soc Hematol 2003 (abstr 628)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.02.050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:39:55Z","timestamp":1653511195000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.02.050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,1]]}},"alternative-id":["10.1200\/JCO.2005.02.050"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.02.050","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}